Company intelligence / Profile preview
NeuCen Biomedical
Taiwan
- Ownership
- Private
- Development stage
- Other
01
Overview
NeuCen Biomedical is a Taiwan-based biotechnology company developing products for cancer and immune-related diseases, including CEN501, a nasal immunotherapy kit for allergic rhinitis that has reached clinical stage, and NEU001, an innovative drug for nasopharyngeal carcinoma in preclinical development.[1][2][3] ABVC BioPharma has been engaged to provide clinical services for advancing CEN501 and NEU001.[4]
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small moleculeAllergen extractDevice
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
ABVC BioPharmaNeOnc Technologies Holdings
Beyond the preview
Go deeper on NeuCen Biomedical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeuCen Biomedical.